ALNY's ENDEAVOUR Goes In Vain, ALQA Gains Big In After-Hrs, SCYX On The Move

Shares of Alnylam Pharmaceuticals Inc. (ALNY) plunged more than 41% in extended trading on Wednesday on news of the company's decision to discontinue its phase III study of Revusiran for the treatment of hereditary ATTR amyloidosis with cardiomyopathy.

from RTT - Biotech http://ift.tt/2dNnqcE
via IFTTT